SOHO 2021 | Treating newly diagnosed myeloma: a changing landscape
Nina Shah, MD, of the University of California, San Francisco, CA, talks on the optimal time to initiate therapy for newly diagnosed multiple myeloma (NDMM), and how the induction therapy landscape is evolving. Dr Shah outlines the key trials studying combination treatment with three or more agents such as the GRIFFIN trial (NCT02874742) investigating daratumumab, lenalidomide, bortezomib, and dexamethasone versus lenalidomide, bortezomib, and dexamethasone for NDMM. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Nina Shah, MD, has received research funding from Celgene/BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar and Precision Biosciences; and has participated in an advisory role with GSK, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm, Oncopeptides and CSL Behring.
